A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain
Phase 4
Completed
- Conditions
- Chronic Pain
- Interventions
- Registration Number
- NCT02289261
- Lead Sponsor
- Cukurova University
- Brief Summary
The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.
- Detailed Description
We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- patients with chronic cancer pain
- between 20-80 years old age
Exclusion Criteria
- the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal)
- psychiatric or neurologic disease
- unable to communicate verbally
- nausea and vomiting
- patient's refusal
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Morphine plus dexmedetomidine Morphine plus dexmedetomidine Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval Control Morphine Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
- Primary Outcome Measures
Name Time Method Morphine consumption (mg) 24 hours cumulative morphine consumption for 24 hours
- Secondary Outcome Measures
Name Time Method Pain score 24 hours visual analog scale to assess pain degree
Trial Locations
- Locations (1)
Cukurova University Faculty of Medicine Research Hospital
🇹🇷Adana, Turkey